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ABSTRACT 
A sensitive, selective, rapid, precise, and economic stability indicating Reverse Phase High Performance Liquid Chromatographic (RP-HPLC) 
method were developed for the quantification of Brexpiprazole in bulk and pharmaceutical dosage form was performed on Shimadzu Model 
HPLC 3000 series, using a mixture methanol and water  (90:10, v/v) with OPA as mobile phase with a flow rate of 0.9 mL/min. D etection was 
carried at 215nm. The retention time of Brexpiprazole was 5.099min. Linearity was observed over the concentration range of 10–50 μg/mL (R2 
= 0.9989) with regression equation y = 71185x-482587.The Accuracy study was performed % recovery of Brexpiprazole. The % recovery was 
found to be 50%=100.13%,100%=99.58%,150%=99.84%.(NLT 98% and NMT 102%). The Relative standard deviation values for intraday 
precision and intraday precision were found to be less than 2% i.e. 0.25% and 0.40% respectively. Brexpiprazole was subjected to stress 
conditions (acidic, alkaline, oxidation and thermal degradation) and validated as per ICH guidelines. The validated method can be applied to 
perform long-term and accelerated stability studies of Brexpiprazole formulations.  
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1. INTRODUCTION: 
Brexpiprazole is an antipsychotic medication. It works by 
changing the actions of chemicals in the brain. Brexpiprazole 
is used to treat the symptoms of schizophrenia. It is also used 
together with other medications to treat major depressive 
disorder in adults. Brexpiprazole is a novel D2 dopamine and 
serotonin 1A partial agonist, called serotonin-dopamine 
activity modulator (SDAM), and a potent antagonist of 
serotonin 2A receptors, noradrenergic alpha 1B and 2C 
receptors. Brexpiprazole is chemically designated as 7-{4-[4-
(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}-1,2-
dihydroquinolin-2-one. Its molecular formula is 
C25H27N3O2S, and its molecular weight is 433.57. 
Brexpiprazole is a white-to-off white powder. 
Literature survey revealed that Brexpiprazole was 
determined by UV-Visible spectroscopy and HPLC. In the 
present study, the authors have proposed simple validated 
spectrophotometric methods for the determination of 
Brexpiprazole in pharmaceutical dosage forms. At present, 
the authors have developed stability indicating RP-HPLC 
method for the determination of Brexpiprazole.[1,2] 
 
Fig No:1 Structure of Brexpiprazole. 
2. MATERIAL AND METHOD: 
 2.1. Equipments:  
HPLC System: 
The method was performed on Shimadzu Model HPLC 3000 
series. With colum  Grace C8 (250mm x 4.6 i.d., particle size: 
5 micron). UV-3000-M Detector has been used for detection 
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and P-3000-m Reciprocating (40MPa) pump are included in 
system. 
Balance: 
All drug and chemical were weighed on Wenser High 
Precision Balance (Model:PGB 100) 
Sonicator: 
Wenser ultra sonicator (WUC-4L) 
Hot air oven: kumar laboratory oven 
Photo stability chamber: make newtronic. Model IC DAC 
(version 1.2) 
Calibrated glassware’s   
2.2. Materials:  
Pharmaceutically pure sample of Brexpiprazole were 
obtained as gift samples from Macelods pharmaceutical Pvt. 
Ltd. Unit V GIDC, Sarigam, Gujrat State, India. HPLC grade 
Methanol (Merck).OPA(Rankem),was used. Brand name: 
Rexulti, Otsuka Pharmaceutical Co, Ltd, Tokyo, Japan 
2.3.Mobile Phase: 
Mobile Phase containing Methanol:water(90:10) with pH 3 
adjusting by OPA .  
2.4.Stock solution of Brexpiprazole: 
Standard stock solution of Brexpiprazole was prepared by 
weighing accurately 100 mg of pure drug of Brexpiprazole  
transfer in 100 mL volumetric flask containing mobile Phase 
to get concentration 1000 µg/mL in 100mLand stock 
solutions was degassed by sonicated at 25 o c for 15 min. For 
working standard solution further dilution was made by 
using proper concentration of standard stock solution. the 
volume was made in Mobile Phase to get final concentration 
range of Brexpiprazole 10,20,30,40,50 µg/mL. 
2.5. Preparation of Sample Solutions of Brexpiprazole: 
Twenty tablets were weighed and make fine powdered; 
powder equivalent to 4 mg  of Brexpiprazole was transferred 
into 10 mL volumetric flask containing Methanol and Water 
(90:10) to get volume up to the mark and  solutions was 
degassed by sonicated at 25 o c for 15 min. This will be 
produced sample solution containing Brexipprazole 400 
ug/ml. 
 
3. RESULT AND DISCUSSION: 
Selection of Analytical Wavelength: 
From the standard stock solution further dilutions were 
done using methanol and water scanned over the range of 
200 – 400 nm. The spectrum was obtained. It was observed 
that the drugs showed considerable absorbance at 215nm so 
it was selected as detection wavelength 
 
Selection of Mobile Phase: 
The standard solution of Brexpiprazole was injected into the 
HPLC system and run in different solvent systems. Different 
mobile phases like  methanol and water  in varying 
proportion of mobile phase components, varying conditions 
of pH were tried in order to obtain the desired system 
suitability parameters for the Brexpiprazole  After several 
trials, Methanol And Water with OPA  was chosen as the 
mobile phase, which gave good resolution and acceptable 
peak parameters. 
 
Fig No:02 UV spectrum of Brexpiprazol 
 
Table 1: Trials of mobile phases for HPLC method of 
Brexpiprazole 
S.N. Mobile Phase Observation 
1. Methanol+ 
Water 
(80:20) 
RT-10.813 
Poor and broad peak with 
another peaks. 
2 Methanol+ 
Water 
(90:10) 
RT- 13.713 
Poor and broad peak with 
another peaks. 
3 Methanol+ 
Water, OPA, PH 3 
(90:10) 
RT-5.099 
broad peak of 
Brexpiprazole 
 
System Suitability Parameter of Drug: 
The column was equilibrated with the mobile phase 
(indicated by constant back pressure at desired flow rate). 
Working standard solution of drug was injected into the 
system. The retention time for the drug was found to be: 
 Brexpiprazole: 5.099ml/min System suitability parameters 
of Brexpiprazole are summarized in table.  
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Fig.No:.03 Optimized chromatographic condition 
Retention Time Area Resolution T.Plate num Asymmetry 
   5.099 586480 0.0    8290  1.09    
 
Method Validation: 
Linearity: 
Linearity of the analytical method was performed by using 
five different concentration of standard stock solution (10-
50ppm) The response factors were plotted against the 
corresponding concentrations of Brexpiprazole obtain in the 
calibration curve for Brexpiprazole. 
Table 2: Linearity Parameter: 
S.N. Concentration 
µg/ml 
Peak Area 
1 10 237185 
2 20 962099 
3 30 1590373 
4 40 2395273 
5 50 3079829 
 
 
Fig No:04  Linearity Graph Of Brexpiprazole 
Assay (%): 
Accurately weigh and transfer 10mg of pure Brexpiprazole 
was transferred  into 10ml clean and dry voilumteric flask. 
Add diluents and sonicated to dissolve it completely and 
made volume upto the mark with the same solvent (mobile 
phase). From this solution appropriate dilution of 
Brexpiprazole were made to get the final concentration and 
finally the solutions were filtered through Whatman filter 
paper. A 20ul sample was injected under chromatographic 
condition. The peak areas were measured at 215nm and the 
percent purity and % RSD was calculated. 
 
Table 3: Assay Of Bulk 
Drug Name Composition in ppm Area of Standard Aomunt found in ppm % Assay 
Brexpiprazole 30 ppm 2080373 29.90 99.67% 
 
Assay of Marketed formulation: 
Twenty tablets were weighed and make fine powdered; 
powder equivalent to 4 mg  of Brexpiprazole was transfred 
into 10 mL volumetric flask contaning Methanol and Water 
(90:10) to get volume up to the mark and  solutions was 
degassed by sonicated at 25 o c for 15 min.This will be 
produced sample solution containing Brexipprazole 400 
ug/ml
  
Table 4: Assay of Marketed formulation 
Drug Name Composition in ppm Area of Standard Area of Sample % Assay 
Brexpiprazole 30 ppm 2080373 2073389 99.66% 
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Accuracy: 
Recovery studies were carried out by addition of standard 
drug to the soln at 3 different concentration levels ( 50%, 
100%, 150% )taking into consideration percentage purity of 
added bulk drug samples. These solutions were subjected to 
re-analysis by the proposed method and results are 
calculated.
 
Table 5: Result of Recovery studies. 
Conc 
(%) 
Sample amount 
(ppm) 
Amount added 
(ppm) 
Area of sample % recovery %mean 
recovery 
50% 20 10 1660341 99.67% 100.13% 
20 10 1656128 99.07%  
20 10 1665328 100.3%  
100% 20 20 2378996 100.3% 99.58% 
20 20 2381273 100.4%  
20 20 2386276 100.08%  
150% 20 30 3065713 99.03% 99.84% 
20 30 3089741 100.01%  
20 30 3071645 99.30%  
 
Precision: 
Precision is expressed as the closeness of agreement 
between a series of measurements obtaining from multiple 
sampling of the same homogeneous sample. The precision 
method was demonstrated by inter-day and intra-day 
studies. Three replicate injections of a known concentration 
of Brexpiprazole  has been injecting into HPLC and analyzed. 
Inter-day study: 
A standard solution containing (30ppm) of Brexpiprazole 
were analyzed three times on the same day and % RSD was 
calculated . The result are given in table  
         Table No: 06 Result of Inter-day studies 
Brexpiprazole 
Day 1 
Area 
1590373 
1593551 
1595666 
Day2 
1581574 
1580048 
1586199 
Mean 1586199 
SD 3202.97 
%RSD 0.40% 
 
Intra-day study: 
A standard solution containing (30ppm) of Brexpiprazole 
were analyzed three times on the same day and % RSD was 
calculated. The result are given in table .     
Table 7:  Result of Intraday studies 
Brexpiprazle 
Morning 
Area 
1590373 
1593551 
1595666 
Evening 
1596366 
1589294 
1586044 
Mean 1591882 
SD 5277.61 
%RSD 0.25 % 
              
6 Robustness: 
Robustness of the method was determined by carrying out 
the analysis under conditions during which flow rate, 
wavelength, were altered and the effects on the peak area 
were note. 
 
Table 8: Result of Robustness 
hanges in parameters Values Area 
Theoretical 
plates 
Mean SD 
%SD 
 
Control As per method 962099 9047    
Flow rate 
(± 0.1 mL/min) 
0.8 mL/min 961516 7950    
1.0 mL/min 960619 7805 961411 745.531 0.077 
control As per method 962099 9097    
Change in Wavelength 
(± 5 nm) 
213nm 962994 7750 962677 501.345 0.052 
217 nm 962938 7564    
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Ruggedness: 
Ruggedness was tested for the rang of concentration 10-
50ppm  
Table 9: Result of Ruggedness 
S.N. Concentration µg/ml Peak Area 
1 10 236575 
2 20 965495 
3 30 1586542 
4 40 2386276 
5 50 3082830 
 
 
Fig No:05 Ruggedness Graph Of Brexpiprazole 
Data for LOD and LOQ Limit of Detection (LOD) and 
Limit of Quantification (LOQ): 
LOD and LOQ were calculated from the average slope and 
standard deviation from the calibration curve as per ICH 
guidelines. LOD was calculated by using this formula 
LOD =  3.3 x Std. Deviation 
 
Slope 
 
LOQ =  10 x Std.  Deviation 
 
Slope 
Where, 
Std. Deviation calculated from accuracy, 
And slope from linearity  
S.N. Drug LOD LOQ 
1 Brexpiprazole 0.55 µg/ ml 1.68 µg/ ml 
 
Stress degradation studies of bulk drug: 
Stress degradation studies were carried under condition of 
acid, base, neutral hydrolysis, oxidation, dry heat and 
photolysis as per ICH Q1A R2 and Q1B Brexpiprazole were 
subjected to variety of stress conditions to affect 
degradation up to about 5-20%. 
.  
Table 10: Summery of Forced Degradation studies of Brexpipzrazole 
S.N. Degradtion Std area Sample 
Area 
Degraded up to 
% 
Actual % 
Degradation 
1 Acid Degradtion 3079829 2658580 86.32% 13.67% 
2 Alkaline Degradtion 3079829 2701042 87.70% 12.29% 
3 Peroxide Degradtion 3079829 2830779 91.91% 8.08% 
4 Thermal Stress Degradtion 3079829 2874629 93.33% 6.66% 
5 Photolytic Stress Degradtion 3079829 2987965 97.01% 2.98% 
 
CONCLUSION 
The proposed simultaneous estimation and validation 
method was found to be simple, precise, accurate and rapid 
for the determination  of Brexpiprazole. The coefficient of 
correlation was obtained in acceptable range .The 
percentage recovery obtained in acceptable range .variation 
in flow rate, wavelength, does not have any effect on the % 
RSD of standard and assay value. The relative standard 
deviation of main peak area ,tailing factor and theoretical 
plate  is well within the acceptable range . Hence the 
precision of given method is confirmed. Brexpiprazole shows 
significant degradation in acid, base, peroxide, thermal and 
UV Competitively, more degradation was found with acid and 
base degradation. Thus from the above result of the 
individual method is conclude that the analytical method is 
validated and found to be satisfactory. 
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